赢率方法在贝叶斯监测中用于具有多个时间至事件终点的两臂II期临床试验设计
针对具有多个时间至事件终点的两臂随机II期试验,提出一种贝叶斯无效性监测设计,采用赢率方法考虑各终点的临床优先级,并假设联合对数正态分布建模。模拟研究显示,与时间至首次事件方法相比,该设计可在高临床优先级终点(如死亡)于治疗组恶化时提前终止无效,而在低临床优先级终点(如癌症复发)恶化时避免激进的提前终止。
要点
- 提出贝叶斯无效性监测设计,利用赢率方法纳入多个时间至事件终点的临床优先级。
- 模拟研究比较显示,该设计在高优先级终点恶化时可提前终止,低优先级终点恶化时避免激进终止。
- 该方法为具有多个时间至事件终点的临床试验提供更量身定制的决策方法。
核心结论
- 所提出的设计允许在高临床优先级终点(如死亡)于治疗组恶化时提前终止无效,而时间至首次事件方法则不能;同时在低临床优先级终点(如癌症复发)于治疗组恶化时避免激进的提前终止,为多时间至事件终点的临床试验提供更量身定制的决策方法。
研究设计与样本
- 提出一种针对两臂随机II期试验的贝叶斯无效性监测设计,采用赢率方法考虑多个时间至事件终点的临床优先级,并假设联合对数正态分布对时间至事件变量建模以进行估计。
- 通过模拟研究评估所提出监测设计的操作特征,并与传统方法进行比较。
主要发现
- 模拟研究显示,与时间至首次事件方法相比,所提出的设计在高临床优先级终点(如死亡)于治疗组恶化时可提前终止无效。
- 所提出的设计在低临床优先级终点(如癌症复发)于治疗组恶化时避免激进的提前终止。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To assess the preliminary therapeutic impact of a novel treatment, futility monitoring is commonly employed in Phase II clinical trials to facilitate informed decisions regarding the early termination of trials. Given the rapid evolution in cancer treatment development, particularly with new agents like immunotherapeutic agents, the focus has often shifted from objective response to time-to-event endpoints. In trials involving multiple time-to-event endpoints, existing monitoring designs typically select one as the primary endpoint or employ a composite endpoint as the time to the first occurrence of any event. However, relying on a single efficacy endpoint may not adequately evaluate an experimental treatment. Additionally, the time-to-first-event endpoint treats all events equally, ignoring their differences in clinical priorities. To tackle these issues, we propose a Bayesian futility monitoring design for a two-arm randomized Phase II trial, which incorporates the win ratio approach to account for the clinical priority of multiple time-to-event endpoints. A joint lognormal distribution was assumed to model the time-to-event variables for the estimation. We conducted simulation studies to assess the operating characteristics of the proposed monitoring design and compared them to those of conventional methods. The proposed design allows for early termination for futility if the endpoint with higher clinical priority (e.g., death) deteriorates in the treatment arm, compared to the time-to-first-event approach. Meanwhile, it prevents an aggressive early termination if the endpoint with lower clinical priority (e.g., cancer recurrence) shows deterioration in the treatment arm, offering a more tailored approach to decision-making in clinical trials with multiple time-to-event endpoints.
引用
- Huang X, Wang J, Ning J, et al. The Win Ratio Approach in Bayesian Monitoring for Two-Arm Phase II Clinical Trial Designs With Multiple Time-To-Event Endpoints. Stat Med. 2024. PMID: 39582325. doi:10.1002/sim.10282
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。